← Human Trials & Peer-Reviewed Studies
Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation
Plain-language guide to PMID 20838781 (2010): clinical trial study of Teriparatide and Parathyroid Hormone (PTH 1-84), osteoporosis and bone density.
Key Facts
- PMID
- 20838781
- Journal
- Calcified tissue international
- Year
- 2010
- Study type
- Clinical Trial
- Authors
- Sridharan M et al. (7 authors)
- DOI
- 10.1007/s00223-010-9414-8
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at Teriparatide and Parathyroid Hormone (PTH 1-84) in the context of osteoporosis and bone density.
Uncertainties exist regarding whether FGF-23 production is influenced by PTH and its involvement in bone formation.
The researchers evaluated FGF-23 response and its relation to changes in biomarkers of bone formation following intermittent PTH treatment.
Who Took Part
PubMed indexes the participants as older adults and people over 80, women only.
Twenty-seven women with a mean [SD] age of 75.8 [5.4] years with postmenopausal osteoporosis were treated with PTH(1-34) for 18 months.
How the Study Was Run
The timeline in the abstract includes 18 months.
Bone mineral density (BMD) was measured at 6 and 18 months at the lumbar spine (LS) and total hip (TH).
Serum calcium, phosphate, PTH, 25(OH)vitamin D, 1,25(OH)(2)vitamin D, markers of bone turnover, FGF-23, and sclerostin were measured.
What Was Measured
The researchers evaluated FGF-23 response and its relation to changes in biomarkers of bone formation following intermittent PTH treatment.
The subject headings attached to it are Biomarkers, Bone Density, Bone Morphogenetic Proteins, Fibroblast Growth Factor-23, Fibroblast Growth Factors, Osteogenesis and Osteoporosis, Postmenopausal.
What This Means in Plain Language
This is a clinical trial of Teriparatide and Parathyroid Hormone (PTH 1-84) in people with osteoporosis and bone density over 18 months.
The publication is from 2010 (Calcified tissue international), a journal based in United States.
More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, Osteoporosis and bone density research.
Our Notes on the Compounds
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
- Osteoporosis and bone density research
- Teriparatide in the library
- Parathyroid Hormone (PTH 1-84) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.